Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. A national multicentre study of 51 cases in clinical practice.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Atienza-Mateo B
- Martín-Varillas JL
- Graña J
- Espinosa G
- Moriano C
- Pérez-Sandoval T
- García-Armario MD
- Castellví I
- Olivé A
- Ybáñez A
- Martinez-Ferrer A
- Narváez J
- Romero-Yuste S
- Ojeda S
- Ros I
- Loricera J
- Calvo-Río V
- Castañeda S
- Gonzalez-Gay MA
- Blanco R
- Spanish Collaborative Group of Refractory Behçet's Disease
Grupos
Abstract
The objective of the present study was to assess the efficacy of apremilast (APR) in the management of refractory oral and/or genital ulcers in patients with Behçet's disease (BD).
Datos de la publicación
- ISSN/ISSNe:
- 0392-856X, 1593-098X
- Tipo:
- Article
- Páginas:
- 69-75
- PubMed:
- 33331268
- Factor de Impacto:
- 1,184 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY CLINICAL & EXPER RHEUMATOLOGY
Documentos
- No hay documentos
Portal de investigación